MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC

September 6, 2014

MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC

The ADRI, together with biotech company EnGeneIC, is running an early stage clinical trial of a new approach to therapy for selected patients with malignant pleural mesothelioma or non-small cell lung cancer. The trial aims to test optimal dose of TargomiRs, an experimental medication consisting of ADRI’s microRNA mimic encapsulated in EnGeneIC’s targeted EDV(TM)nanocells, and is being carried out at three Sydney hospitals: Concord Repatriation General Hospital, Royal Prince Alfred Hospital/ Lifehouse, and Royal North Shore Hospital.

For more information about this trial, please contact Jocelyn McClean at jocelyn.mclean@sydney.edu.au